Outcomes
Table 3 compares treatment outcomes between patients who developed AKI and those who did not. Renal replacement therapy was performed in 3 patients (20% of the severe AKI patients). After the first cycle of chemotherapy, 77 patients (68.8%) had complete bone marrow remission. The proportion of patients with remission was significantly lower in the AKI group than in the non-AKI group (58.9% vs 78.6%, P = 0.041); however, there were no significant differences in the survival rates (Figure 2). Overall, there were 87 (77.7%) deaths in our cohort and the median survival time was 8.4 months (IQR 3.8-19.9).